XML 49 R39.htm IDEA: XBRL DOCUMENT v3.23.2
Equity (Details)
$ / shares in Units, $ in Thousands, shares in Millions, dose in Millions
1 Months Ended 2 Months Ended 3 Months Ended 6 Months Ended
Mar. 18, 2021
USD ($)
dose
May 31, 2023
USD ($)
$ / shares
shares
Jun. 30, 2022
USD ($)
Feb. 28, 2022
USD ($)
$ / shares
shares
Feb. 28, 2023
USD ($)
shares
Jun. 30, 2023
USD ($)
dose
$ / shares
Jun. 30, 2023
USD ($)
dose
$ / shares
Jun. 30, 2022
USD ($)
Dec. 31, 2022
USD ($)
$ / shares
Dec. 31, 2021
USD ($)
Mar. 01, 2021
$ / shares
shares
Subsidiary, Sale of Stock [Line Items]                      
Issuance costs             $ 222 $ 200      
Convertible preferred stock, par value (in USD per share) | $ / shares           $ 0.01 $ 0.01   $ 0.01    
Series B Warrants                      
Subsidiary, Sale of Stock [Line Items]                      
Preferred stock issued           $ 1 $ 1   $ 1 $ 5,000  
Preferred stock, outstanding                 $ 4,100    
Asset impairment charges           $ 4,100 $ 4,100        
Series B Warrants | Level 3 | Discount Rate                      
Subsidiary, Sale of Stock [Line Items]                      
Preferred stock, measurement input                   0.15  
Public Offering Of Common Stock                      
Subsidiary, Sale of Stock [Line Items]                      
Number of shares issued and sold (in shares) | shares   30.0   16.0              
Proceeds from sale of stock   $ 14,800   $ 49,800 $ 5,600            
Price per share (in USD per share) | $ / shares   $ 0.50   $ 3.13              
Issuance costs         $ 200            
ATMs                      
Subsidiary, Sale of Stock [Line Items]                      
Number of shares issued and sold (in shares) | shares         4.5            
Aggregate gross number of shares that may be issued in transaction, value     $ 160,000                
COVAXIN Preferred Stock Purchase Agreement | Series B Warrants                      
Subsidiary, Sale of Stock [Line Items]                      
Agreement to sell, number of shares issued in transaction (in shares) | shares                     0.1
Convertible preferred stock, par value (in USD per share) | $ / shares                     $ 0.01
Agreement to sell, price per share (in USD per share) | $ / shares                     $ 109.60
Advance payment amount $ 6,000                    
Conversion ratio (in shares)                     10
Supply agreement, number of doses | dose 10.0         10.0 10.0